Coronary artery disease in uremia: Etiology, diagnosis, and therapy

Kidney International

Volumn 60, Issue 6, 2001, Pages 2059-2078

  Goldsmith, David J A ^a   Covic, Adrian ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme; Asprin; Computed tomography; Electrocardiography; Heparin; Low density lipoprotein

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCINEURIN INHIBITOR; CALCIUM PHOSPHATE; CLOPIDOGREL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HEPARIN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; NICORANDIL; NITRATE; PARATHYROID HORMONE; PRAVASTATIN; TICLOPIDINE; VITAMIN D;

ANEURYSM; ATHEROGENESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; DIAGNOSTIC PROCEDURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART VALVE SURGERY; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; KIDNEY FAILURE; MORBIDITY; OPEN HEART SURGERY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; UREMIA;

EID: 0035187621     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00040.x     Document Type: Article

References (171)

1. Report on management of renal failure in Europe, XXII, 1991
2. Controlling the epidemic of cardiovascular disease in chronic renal failure: What do we know? What do we need to learn? Where do we go from here?
3. Cardiovascular risk factors and diseases after renal transplantation
4. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
5. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
6. Accelerated atherosclerosis in prolonged maintenance hemodialysis
7. Hypertension and accelerated atherosclerosis in endstage renal disease
8. Cardiovascular disease in patients with chronic renal failure
9. Lipoprotein(a) in renal disease
10. Causes, risks and therapy of hyperlipidaemia in chronic dialysis patients
11. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
12. Lipoprotein(a), homocysteine, and remnant like particles: Emerging risk factors
13. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study
14. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients
15. The microinflammatory state of uremia
16. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome)
17. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
18. Is renal insufficiency an atherogenic state? Reflections on prevalence, incidence, and risk
19. Cardiological problems in uraemic patients (chapt 9.6.2)
20. Screening diabetic transplant candidates for coronary artery disease: Identification of a low risk subgroup
21. Coronary angiography and coronary artery by-pass grafts in diabetics
22. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure
23. Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis
24. Cardiovascular disease in uremic patients on hemodialysis
25. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
26. Hyperphosphataemia - A silent killer of patients with renal failure
27. The impact of calcification on the biomechanical stability of atherosclerotic plaques
28. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy
29. The low molecular weight Apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up
30. Angiographic progression of coronary artery disease in patients with end-stage renal disease
31. Outcome and risk factors of ischemic heart disease in chronic uremia
32. Coronary artery inflammation and thrombosis in Wegener’s granulomatosis - Polyarteritis nodosa overlap syndrome
33. Necrotizing myocardial vasculitis in Churg-Strauss syndrome: Clinicohistologic evaluation of steroids and immunosuppressive therapy
34. Cardiopulmonary manifestations of Henoch-Schönlein purpura
35. Giant coronary artery aneurysms and myocardial infarction in a patient with systemic lupus erythematosus
36. Acute myocardial infarction with normal coronary arteries as initial manifestation of polyarteritis nodosa. A case report
37. Inflammatory diseases of the coronary artery in children
38. Prinzmetal’s angina pectoris revealing aneurysm of the right coronary artery during evolution of Churg-Strauss syndrome
39. Bilateral common iliac artery aneurysms secondary to fibromuscular dysplasia accompanied with a coronary aneurysm. A case report
40. Coronary aneurysms in patients with autosomal dominant polycystic kidney disease
41. Microvascular disease - The Cinderella of uraemic heart disease
42. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure
43. Amyloidosis limited to small arteries causing angina pectoris and sudden death
44. Cutaneous necrosis from calcific uremic arteriolopathy
45. Systemic lupus erythematosus: Calciphylaxis induced cardiomyopathy
46. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis
47. The epidemiology of coronary artery disease in patients on maintenance hemodialysis: Implications for management
48. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine
49. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients
50. Characteristics of myocardial ischemia in patients with chronic renal failure and its relation to cardiac sympathetic activity
51. Myocardial interstitial fibrosis in uraemia: Is it relevant?
52. Impairment of cardiac function and energetics in experimental renal failure
53. The function of the aorta in ischemic heart disease: A magnetic resonance and angiographic study of aortic compliance and blood flow patterns
54. Pulse wave analysis
55. Coronary artery disease in 100 diabetic with end-stage renal failure
56. Coronary angiography prior to renal transplantation
57. Prevalence of central autonomic neuropathy in elderly dialysis patients
58. Coronary artery disease in dialysis patients
59. QRS amplitude and volume changes during hemodialysis
60. Frequency of painless myocardial ischemia during hemodialysis in 50 patients with chronic kidney failure
61. Painless myocardial ischemia in chronic hemodialysed patients: A real event?
62. Coronary artery disease in dialysis patients
63. Current markers of myocardial ischemia and their validity in end-stage renal disease
64. Troponin T, a predictor of death in chronic haemodialysis patients
65. Cardiac troponin I in patients receiving renal replacement therapy
66. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran’s Hospital: A pilot study
67. Cardiac troponin T predicts mortality in patients with end-stage renal disease
68. Cardiac troponin T predicts long-term outcomes in hemodialysis patients
69. False positive analytical interference of cardiac troponin I assays: An important consideration for method selection
70. Expression of cardiac troponin T isoforms in skeletal muscle of renal disease patients will not cause false-positive serum results by the second generation cardiac troponin T assay
71. Value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: A 9-month outcome analysis
72. Impact of renal cadaveric transplantation on survival in end-stage renal failure: Evidence for reduced mortality risk compared with hemo-dialysis during longterm follow-up
73. Screening for coronary artery disease
74. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure
75. Perfusion thallium imaging of type I diabetic patients with end-stage renal disease: Comparison of oral and intravenous dipyridamole administration
76. Prospective risk stratification in renal transplant candidates for cardiac death
77. Echocardiographic findings in long-term, long-hour hemodialysis patients
78. Long-term changes in left ventricular hypertrophy after renal transplantation
79. Early echocardiographic changes and survival following renal transplantation
80. Usefulness of dobutamine stress-echocardiography in detecting coronary artery disease in end-stage renal disease
81. Imaging of coronary artery calcification. Its importance in assessing atherosclerotic disease
82. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
83. Myocardial calcification and cardiac dysfunction in chronic renal failure
84. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients
85. Coronary artery diameter and left ventricular function in patients on maintenance hemodialysis treatment: Comparison between diabetic and nondiabetic patients
86. Calcification of the aortic valve in the dialyzed patient
87. Coronary calcification: Assessment by intravascular ultrasound imaging
88. Angiographic study of stenosis and calcification of coronary vessels in long-term dialysis patients: Examination of risk factors for coronary calcification
89. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients
90. Managing phosphate retention: Is a change necessary?
91. Continuing evolution of therapy for CAD. Initial results from the era of angioplasty
92. Changes in renal function with percutaneous transluminal coronary angioplasty
93. Effects of saline, mannitol and furosemide to prevent acute decreases in renal function induced by radiocontrast agents
94. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine
95. Screening and treatment for cardiovascular disease in patients with chronic renal disease
96. Prospective risk stratification in renal transplant candidates for cardiac death
97. Factors in cardiac risk stratification of candidates for renal transplant
98. Acute myocardial infarction in patients with end-stage renal disease
99. Poor long-term survival of dialysis patients after acute myocardial infarction: Bad treatment or bad disease?
100. Survival after acute myocardial infarction in patients with end-stage renal disease: Results from the co-operative cardiovascular project
101. Long-term outcome of coronary events in hemodialysis patients younger and older than 65 years of age
102. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction
103. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis
104. Determinants of ventricular arrhythmias in hemodialysis patients. Evaluation of the effect of arrhythmogenic substrate and autonomic imbalance
105. Signal-averaged ECG abnormalities in haemodialysis patients. Role of dialysis
106. Effect of hemodialysis on QT dispersion in chronic uremia
107. Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients
108. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
109. Lipid-lowering therapy in patients with renal disease
110. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
111. The effects of normal as opposed to low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoitin
112. Arterial calcification after vitamin D therapy in hyperphosphataemic renal failure
113. Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension
114. Increased platelet volume and platelet mass in patients with ath-erosclerotic renal artery stenosis
115. Circulating aggregated platelets, number of platelets per aggregate and platelet size in chronic dialysis patients
116. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclo-oxygenase inhibition
117. Anti-platelet therapy in graft thrombosis: The results of a prospective, randomized, double-blind study
118. Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts
119. Diagnosis and management of coronary artery disease
120. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
121. Ex vivo - In vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A
122. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
123. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients
124. Management of chronic stable angina: Medical therapy, percutaneous transluminal angioplasty, and coronary artery bypass surgery
125. Angioplasty and stenting in patients with renal disease
126. After myocardial revascularization and renal transplantation: A 25-year single-institution experience
127. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures
128. Long-term outcome of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting in patients with end-stage renal disease
129. Comparison of clinical outcome following coronary stenting or balloon angioplasty in dialysis versus non-dialysis patients
130. Coronary angioplasty in hemodialysis patients
131. Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting
132. Clinical outcomes of PTCA in chronic renal failure: A case-control study for comorbid features and evaluation of dialysis dependence
133. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis
134. A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery
135. Potential mechanisms promoting restenosis in diabetic patients
136. Restenosis after percutaneous transluminal coronary angioplasty in patients with non-insulin-dependent diabetes mellitus (NIDDM)
137. Tissue characteristics of restenosis after percutaneous transluminal coronary angio-plasty in diabetic patients
138. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: A case-control study using quantitative coronary angiography
139. The relative influence of lesion length and other stenosis morphologies on procedural success of coronary intervention
140. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty
141. Aorto-coronary bypass graft surgery in a patient on home hemodialysis
142. Cardiac surgery in patients undergoing renal dialysis or transplantation
143. Cardiac surgery in patients with end-stage renal disease
144. Cardiac surgery for patients maintained on chronic hemodialysis
145. Cardiopulmonary bypass procedures in dialysis patients
146. Coronary artery disease in patients with renal failure
147. Open heart operations after renal transplantation
148. Oxygen consumption in hemodialysis patients undergoing cardiopulmonary bypass
149. Sternal wound complications-Incidence, microbiology and risk factors
150. Multicenter review of preoperative risk factors for stroke after coronary artery bypass grafting
151. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial
152. Histological change of coronary artery bypass graft in a maintenance hemodialysis patient
153. Coronary artery surgery is associated with different forms of atherogenic lipoprotein modifications
154. Potential non-glycoprotein IIb/IIIa effects of abciximab
155. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits
156. Coronary artery bypass grafting in dialysis patients
157. Coronary artery bypass grafting in dialysis patients
158. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients
159. Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients
160. Coronary artery surgery study (CASS): A randomised trial of coronary artery bypass surgery: Survival data
161. Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure
162. The sympathetic nervous system and the kidney: Its importance in renal diseases
163. Comparison of coronary bypass surgery or angioplasty in patients with multi-vessel disease
164. Controversy on optimal blood pressure on haemodialysis: Normotensive blood pressure values are essential for survival
165. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men
166. Impact of immunosuppressive therapy on hypertension
167. Impact and management of hyperlipidaemia post-transplantation
168. Impact and management of post-transplant diabetes mellitus
169. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression
170. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro
171. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data